Abstract
OBJECTIVE: To analyze the correlation between ultrasound data and Her-2 and CD147 expressions in breast carcinoma. METHOD: A retrospective analysis was conducted on 95 patients with invasive breast carcinoma, hospitalized during March 2021 to May 2024, designated as the breast cancer group. Additionally, 80 cases with benign breast lesions were selected as the control group. Contrast-enhanced ultrasound (CEUS) was performed on both groups. Immunohistochemistry was used to detect the expression of Her-2 and CD147 proteins in breast cancer and adjacent tissues, while RT-qPCR was employed to measure the mRNA expression of Her-2 and CD147 in the cancer and adjacent tissues. RESULTS: The peak time in the breast cancer group was shorter than in the control group (P<0.05). Conversely, the enhancement amplitude, slope of ascending branch, area under the curve, and gradient were higher in the breast cancer group than in the control group (all P<0.05). There was a significant negative correlation between peak time of ultrasound parameters and the relative expression of Her-2 and CD147 mRNA (P<0.05). In contrast, the enhancement amplitude, slope of the ascending branch, area under the curve, and gradient exhibited positive correlations with the relative expression of Her-2 and CD147 mRNA in cancer tissues (P<0.05). CONCLUSION: The contrast-enhanced ultrasound data of malignant breast tumors significantly differed from those of benign tumors, demonstrating good diagnostic value for breast cancer. In addition, these ultrasound data were significantly correlated with the expression of Her-2 and CD147 in tumor tissues, providing valuable insight for the non-invasive assessment of early-stage breast cancer and offering a reference for diagnosis and treatment planning.